SpliceBio
@SpliceBioHQ
Genetic medicines company harnessing Protein Splicing to develop the next-gen of gene therapies. Based on technology developed in the Muir Lab at @Princeton.
Today @SpliceBioHQ announces a 50M€ Series A to advance our Protein Splicing platform and expand our gene therapy pipeline. Financing co-led by @ucb_news (Ventures) & @YsiosCapital and joined by @NEA, @GildeHealthcare, @Novartis (NVF) and @AsabysPartners. prnewswire.com/news-releases/…
📢 #SpliceBio features on #OptimumTV with EQT Life Sciences! 📺 Go behind the scenes of our $135M Series B + discover how our Protein Splicing technology sets us apart in gene therapy. Hear from our CEO & EQT Life Sciences👇
Everyone knows the financing environment is tough right now. But that hasn’t stopped @SpliceBioHQ securing $135m in a Series B to advance its genetic medicines, including its lead programme SB-007 for the eye condition #Stargardt disease. Watch Miquel Vila- Perelló talk to…
Don’t miss @CataloniaHealth’s BBQ 2025! ☀️#SpliceBio is proud to be a sponsor of this key biotech event. Join 400+ health innovators for an evening of networking & celebration! 📅 July 10 📍 Barcelona #Biotech #LifeSciences
📽️ Tune in to @CGT_Insights's webinar to hear from our VP of Regulatory Affairs & Quality, Leigh Shaw! A panel of experts will explore the evolving CGT regulatory landscape with a focus on patient safety. 📅 1 July | 🕓16:00 BST / 17:00 CEST 🔗 Register: bit.ly/3I9Aw1O
#Stargardtdisease patients currently have no approved treatments for this inherited retinal disorder. Our lead gene therapy, SB-007, is designed to address the underlying genetic cause of the disease with the potential to treat all patients. Discover more: bit.ly/3ZpxYmi
SpliceBio takes over Times Square! 🗽 Proud to see our $135M Series B milestone spotlighted on the iconic @Nasdaq Tower. Huge thanks to our team & investors powering the next wave of genetic medicines! 💡
The @SpliceBio platform is based on technology developed in @MuirLab at @Princeton.
Yesterday, we announced the close of a $135M Series B financing to support clinical development of SB-007 for #StargardtDisease, including the ongoing Phase 1/2 ASTRA and POLARIS studies. Stay tuned as we advance our broader pipeline of genetic medicines. bit.ly/3ZpxYmi
Venue at capacity for @UKEyeGenetics annual conference @StAnnesCollege, Oxford! It is an exciting time to be involved in #ophthalmicgenetics. The diagnostic precision and therapeutic development are at an all-time peak! 👀🧬 We are grateful to our platinum sponsors @SpliceBioHQ
Enjoying a stimulating day of updates in #ophthalmicgenetics the UK Eye Genetics Group annual conference @StAnnesCollege, Oxford! A huge thank you to our platinum sponsor @SpliceBioHQ and our bronze sponsor @Metrovision for their amazing support! #ophthalmology #genetics
Yesterday, we announced the close of a $135M Series B financing to support clinical development of SB-007 for #StargardtDisease, including the ongoing Phase 1/2 ASTRA and POLARIS studies. Stay tuned as we advance our broader pipeline of genetic medicines. bit.ly/3ZpxYmi
We’re proud to close a $135M Series B! Huge thanks to our amazing team & investors whose passion drives next-generation gene therapies. Our Co-Founder & CEO, Miquel Vila-Perelló, shares his thoughts on this milestone and what’s next — read more here: bit.ly/3ZpxYmi
🌟Financing milestone! #SpliceBio closes $135M Series B to: 🚀Advance SB-007 for #StargardtDisease 🔬Expand our genetic medicine pipeline Read more: bit.ly/3ZpxYmi
We’re proud to join the Community Zoom session hosted by @StargardtsC to share clinical progress on our lead program, SB-007 — the first dual AAV gene therapy in clinical development for #StargardtDisease. 📅 31 May 🕛 12:00–1:30 PM BST Register here: bit.ly/4dF9viD
May is #HealthyVisionMonth 👁️We are proud to support the #Stargardtdisease community – this March, we dosed the first patient in our Phase 1/2 ASTRA study! Learn more about our mission to address inherited #retinal diseases: bit.ly/42u9U3Z
Heading to #ASGCT2025? Connect with #SpliceBio in New Orleans! Meet CEO Miquel Vila Perello & CBO Gerard Caelles and learn about SB-007 — the first dual AAV #genetherapy in the clinic for #StargardtDisease. The first patient was dosed in the Phase 1/2 ASTRA study in March 2025.
Meet us in Salt Lake City at #ARVO2025! The #SpliceBio team will be at @ARVOinfo's premier conference for eye & vision specialists from May 4-8. 📅 Learn about our dual AAV gene therapy for #Stargardtdisease, SB-007, and the Phase 1/2 ASTRA study! 🚀
The #SpliceBio team is heading to Salt Lake City for the Retinal Therapeutics Innovation Summit 2025 on 2 May! Excited to share updates on our dual AAV #genetherapy, SB-007, and connect with leaders in #biotech, #ophthalmology & research. #Stargardtdisease.
Barcelona – A Rising Star in the Life Sciences Industry In the article ‘Why biotech is booming in Barcelona,’ @NaturePortfolio explores the unique advantages that make Barcelona a hotbed for breakthrough innovation — featuring our very own #SpliceBio here: bit.ly/42ARCfJ
Heading to #CGMed25 from📅15–17 April? #SpliceBio will be in Rome for Europe’s premier cell & gene therapy conference! Let’s connect and discuss our dual AAV #genetherapy, SB-007, for the treatment of Stargardt disease, currently in Phase 1/2 development in the ASTRA study🚀.
📰 Our Co-Founder and CEO is featured in @Bloomberg! In the latest article, “Big Pharma Is Heading to Barcelona and Here’s Why,” which explores the city’s emergence as a burgeoning biotech hub, Miquel Vila-Perello shares: “I wanted to be part of that.”📍 bit.ly/42cSCq3
This #WorldOptometryDay, 23rd March. We at #SpliceBio are proud to be working alongside the #Stargardtdisease patient community to bring a potential treatment option to patients with our dual-AAV gene therapy, SB-007. SB-007 is advancing in the clinic in a Phase 1/2 ASTRA study.